General SurgeryNMC Grounded

Breast Cancer: TNM Staging, Molecular Subtypes & Surgical Management

Bailey & Love's Short Practice of Surgery 28th Ed · Ch 53 The Breast
Breast Cancer: TNM Staging, Molecular Subtypes & Surgical Management anatomical & clinical diagram
Verified Clinical DiagramBailey & Love's Short Practice of Surgery 28th Ed · Ch 53 The Breast

High-Yield Clinical Pearls & Exam Keys

1

Core Needle Biopsy (Tru-cut) is the diagnostic procedure of choice for breast masses because it preserves tissue architecture to demonstrate basement membrane invasion and allows immunohistochemistry for ER, PR, and HER2.

2

Sentinel Lymph Node Biopsy (SLNB) using radiotracer (Technetium-99m sulfur colloid) and blue dye avoids unnecessary axillary dissection in clinically node-negative (cN0) patients.

3

Breast Conserving Surgery (BCS / lumpectomy with wide margins) combined with postoperative whole-breast radiotherapy yields equivalent overall survival to Modified Radical Mastectomy (MRM).

Ask Dr. Medarro about General Surgery

Instant NMC-grounded answers with standard textbook citations

Or tap a high-yield exam question:

The Golden Rule: Triple Assessment of Breast Lumps

Key #1

1. Clinical Examination (Bilateral breast, axillary and supraclavicular lymph node palpation)

Key #2

2. Imaging (Bilateral Mammography for women ≥ 40 years; High-Resolution Ultrasound for women < 40 years)

Key #3

3. Pathology (Core Needle Biopsy; FNAC cannot distinguish in situ from invasive carcinoma or assess ER/PR/HER2)

Molecular Subtypes of Breast Carcinoma

Molecular SubtypeReceptor Status ProfileTargeted Therapy & Prognosis
Luminal AER+, PR+ (high ≥20%), HER2-neu negative, low Ki-67 (<14%)Endocrine therapy (Tamoxifen / Aromatase Inhibitors); Best overall prognosis
HER2-EnrichedER negative, PR negative, HER2-neu 3+ (amplified)Anti-HER2 targeted therapy (Trastuzumab / Pertuzumab); High recurrence if untreated
Triple-Negative (TNBC / Basal-like)ER negative, PR negative, HER2-neu negative (often BRCA1 associated)Systemic cytotoxic chemotherapy + Immunotherapy (Pembrolizumab); Aggressive, early visceral relapse

Interactive Clinical Vignette Practice

Live Rule-Out Engine
Case Vignette #1NEET-PG Calibrated

A 52-year-old postmenopausal woman undergoes screening mammography, revealing a 1.8 cm spiculated mass in the upper outer quadrant of the right breast with microcalcifications. Physical examination shows no palpable axillary lymph nodes. Core needle biopsy confirms Invasive Ductal Carcinoma (Grade 2, ER positive, PR positive, HER2 negative). What surgical option offers equivalent overall survival to total mastectomy while preserving the breast?

ASimple lumpectomy without margin assessment or radiation
BWide local excision (lumpectomy) with negative margins + Sentinel Lymph Node Biopsy + Postoperative Whole-Breast Radiotherapy
CImmediate radical Halsted mastectomy including pectoralis major excision
DPrimary high-dose systemic chemotherapy followed by watchful observation
Free Student Account Required

Unlock Complete Viva Traps & Additional Case Vignettes

Access model examiner answers, comprehensive rule-out breakdowns, and 4K spotter explanations.

Free student account•No credit card required
Medarro Study Hub

Want 50+ Clinical Vignettes & 4K 3D Spotters on General Surgery?

Practice Spaced Repetition Decathlon, generate instant 7-day adaptive study plans, and upload your college PDFs into the personal vault.

Related High-Yield Chapters